Beskrywing

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 miljoen van 2022 aan 2028, 'n CAGR van 16.1% gedurende die voorspellingsperiode.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2018-2021 en voorspel tot 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, aansoek, biomarker type, tegnologie, en streek. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), ander (bv. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 and is anticipated to hold its share during the forecast period. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, ander. In 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Gebaseer op tegnologie, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), ander. Onder hierdie, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. In terms of geography, the global liquid biopsy market has been segmented into Asia Pacific, Europa, Noord-Amerika, Rest of the World (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Bpk., Becton Dickinson and Company, Berry Genomics Co. Bpk., BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Therapy: oncology, noninvasive prenatal testing (NIPT), ander (bv. organ transplant)
Toepassing: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, ander
Tegnologie: next-generation sequencing (NGS), polymerase chain reaction (PCR), ander
Streek: Asiatiese Stille-Oseaan, Europa, Noord-Amerika, Rest of the World (RoW)
Jare oorweeg: hierdie verslag dek die tydperk 2018 aan 2028

Sleutelvoordele vir belanghebbendes

– Get a comprehensive picture of the global liquid biopsy market
– Bepaal groeisektore en -neigings vir belegging

INHOUDSOPGAWE

Deel 1. Inleiding
– Omvang van die studie
– Studietydperk
– Geografiese omvang
– Navorsingsmetodologie
Deel 2. Liquid biopsy market overview
Deel 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– Ander (bv. organ transplant)
Deel 4. Markverdeling volgens toepassing
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
Deel 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– Ander
Deel 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– Ander
Deel 7. Market breakdown by region
– Asiatiese Stille-Oseaan
– Europa
– Noord-Amerika
– Rest of the World (RoW)
Deel 8. Sleutel maatskappye
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., Bpk.
– Becton, Dickinson and Company
– Berry Genomics Co., Bpk.
– BGI Group
– Biocartis Group
– Biocept, Inc.
– Biodesix, Inc.
– Biolidics Limited
– Bio-Rad Laboratories, Inc.
– Bio-Techne Corp.
– CareDx, Inc.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, Inc.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, Inc.
– NeoGenomics Laboratories, Inc.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, Inc.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
Oor StrategyHelix
Vrywaring